Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILORswitch (PADA-2)
2025-524213-84-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camizestrant and abemaciclib in breast cancer (4 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Planned start Jul 2026; status: authorised.
02
Drugs
camizestrantabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-524213-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524213-84-00.